18,847 Shares in DexCom, Inc. $DXCM Purchased by VestGen Advisors LLC

VestGen Advisors LLC bought a new stake in shares of DexCom, Inc. (NASDAQ:DXCM) in the 3rd quarter, Holdings Channel.com reports. The firm bought 18,847 shares of the medical device company’s stock, valued at approximately $1,626,000.

Several other large investors also recently added to or reduced their stakes in the business. Mather Group LLC. increased its holdings in DexCom by 27.7% during the third quarter. Mather Group LLC. now owns 563 shares of the medical device company’s stock valued at $49,000 after buying an additional 122 shares during the last quarter. Fifth Third Wealth Advisors LLC boosted its stake in shares of DexCom by 2.8% during the 3rd quarter. Fifth Third Wealth Advisors LLC now owns 5,510 shares of the medical device company’s stock worth $475,000 after acquiring an additional 150 shares during the last quarter. Elevation Wealth Partners LLC grew its position in shares of DexCom by 61.0% during the 3rd quarter. Elevation Wealth Partners LLC now owns 401 shares of the medical device company’s stock valued at $35,000 after acquiring an additional 152 shares during the period. MassMutual Private Wealth & Trust FSB grew its position in shares of DexCom by 15.4% during the 2nd quarter. MassMutual Private Wealth & Trust FSB now owns 1,147 shares of the medical device company’s stock valued at $77,000 after acquiring an additional 153 shares during the period. Finally, Simplicity Wealth LLC grew its position in shares of DexCom by 5.4% during the 3rd quarter. Simplicity Wealth LLC now owns 3,169 shares of the medical device company’s stock valued at $273,000 after acquiring an additional 162 shares during the period. 97.75% of the stock is currently owned by institutional investors.

More DexCom News

Here are the key news stories impacting DexCom this week:

• Positive Sentiment: Quarterly results exceeded expectations. DexCom reported revenue of approximately $1.34 billion, up 11.1% year over year, and adjusted earnings of $0.73 per share, surpassing analyst estimates of $0.68. U.S. revenue grew 14%, supported by demand for its continuous glucose monitoring products and adoption of the G7 15 Day system. DexCom Stock Up on Q3 Earnings & Revenue Beat, Margins Rise
• Positive Sentiment: Margins improved materially. Non-GAAP operating margin reached 25.3%, while gross profit increased 18.2% and operating profit rose 34.9% year over year. The stronger earnings profile likely reinforced confidence in DexCom’s growth and cost management. DexCom Q3 2026 Earnings
• Positive Sentiment: Full-year outlook was raised. Management increased the midpoint of its 2026 revenue forecast to a range of $5.20 billion to $5.25 billion and lifted operating-margin and adjusted-EBITDA-margin guidance.
• Positive Sentiment: Shareholder returns received a boost. DexCom authorized a new $1.0 billion share buyback, which could support earnings per share and signal management’s confidence in cash generation. DexCom Announces $1 Billion Equity Buyback
• Positive Sentiment: Analyst sentiment improved. Barclays raised its price target from $115 to $120 while maintaining an “overweight” rating, citing potential upside following the results and improved outlook.
• Neutral Sentiment: Institutional ownership data showed substantial buying by several funds, including Invesco and Arrowstreet, but also significant reductions by other investors. This suggests mixed positioning rather than a clear institutional consensus.
• Negative Sentiment: Insider selling remains a cautionary signal. DexCom insiders reported 26 open-market sales and no purchases over the past six months. A recent sale by EVP Sadie Stern was made under a pre-arranged Rule 10b5-1 plan, reducing its predictive value, but the broader pattern may limit enthusiasm among some investors.

Insider Activity

In other DexCom news, Director Mark G. Foletta sold 2,000 shares of DexCom stock in a transaction on Monday, August 3rd. The shares were sold at an average price of $85.32, for a total value of $170,640.00. Following the sale, the director directly owned 48,852 shares in the company, valued at approximately $4,168,052.64. The trade was a 3.93% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Jereme Sylvain sold 3,638 shares of the business’s stock in a transaction on Thursday, September 10th. The stock was sold at an average price of $83.27, for a total transaction of $302,936.26. Following the completion of the sale, the executive vice president owned 146,828 shares in the company, valued at approximately $12,226,367.56. The trade was a 2.42% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 24,822 shares of company stock valued at $2,090,833 in the last quarter. Company insiders own 0.28% of the company’s stock.

Analyst Ratings Changes

Several research firms have recently commented on DXCM. TD Cowen restated a “buy” rating and issued a $95.00 price objective on shares of DexCom in a research note on Friday, September 18th. UBS Group set a $96.00 target price on DexCom and gave the company a “buy” rating in a research report on Tuesday, July 28th. Barclays boosted their price target on DexCom from $115.00 to $120.00 and gave the company an “overweight” rating in a report on Friday. Citigroup reissued a “buy” rating and set a $88.00 price target (up from $84.00) on shares of DexCom in a report on Friday, July 31st. Finally, BTIG Research upped their price target on DexCom from $90.00 to $96.00 and gave the stock a “buy” rating in a research report on Monday, October 12th. Two investment analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $92.91.

DexCom Price Performance

Shares of DexCom stock opened at $82.29 on Friday. DexCom, Inc. has a 52 week low of $54.11 and a 52 week high of $92.59. The company has a quick ratio of 1.43, a current ratio of 1.73 and a debt-to-equity ratio of 0.47. The company has a market capitalization of $31.05 billion, a price-to-earnings ratio of 32.27, a PEG ratio of 1.34 and a beta of 1.48. The stock’s 50-day simple moving average is $85.82 and its 200-day simple moving average is $74.65.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings data on Thursday, October 29th. The medical device company reported $0.73 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.68 by $0.05. The business had revenue of $1.34 billion during the quarter, compared to analyst estimates of $1.33 billion. DexCom had a net margin of 19.42% and a return on equity of 36.96%. The company’s revenue was up 11.1% on a year-over-year basis. During the same period last year, the firm posted $0.61 EPS. As a group, analysts expect that DexCom, Inc. will post 2.64 earnings per share for the current fiscal year.

DexCom Company Profile

DexCom, Inc develops and commercializes continuous glucose monitoring (CGM) systems for people with diabetes. Its devices use a small wearable sensor to measure glucose levels in real time and transmit readings to compatible smartphones, receivers, smartwatches, and other connected devices, helping users monitor glucose trends and make informed decisions about their health.

The company’s product portfolio includes the Dexcom G7 and Dexcom G6 CGM systems, as well as Dexcom ONE and Dexcom ONE+ products offered in select markets.